Press

Cybin Files an International Patent Application Covering Psychedelic Delivery Methods

Oct 12 • 2 min read

Quick Take: The application, governed by the Patent Cooperation Treaty (“PCT”), brings the potential to obtain patent coverage in 153 countries. Cybin Inc. (NYSE AMERICAN: CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed an international patent application related to methods for the delivery of psychedelic…

Atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression

Oct 11 • 4 min read

Quick Take: PsyProtix is a precision psychiatry company focused on developing therapeutics for treatment-resistant depression (TRD) and other mental health indications. atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the launch of PsyProtix, a new platform company formed with Chymia LLC, a Duke University biotechnology spinout. PsyProtix…

Numinus Upgrades Psychedelics Lab to Increase Research Service Capabilities

Oct 8 • 4 min read

Quick Take: The new space will be dedicated to the following services: Bioanalytical testing, Bioassay and in-vitro studies, Research & development and formulation studies for several psychedelic compounds, including ketamine and LSD, and, Small batch manufacturing. Numinus Wellness Inc. (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to announce the expansion of its psychedelics…

Tryp Therapeutics To Collaborate With Researchers at The University of Wisconsin-Madison

Oct 8 • 3 min read

Tryp Therapeutics (TRYP) a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today a collaboration with Paul Hutson, PharmD and Christopher Nicholas, PhD to support clinical pharmacology studies for the Company’s proprietary drug product, TRP-8803. Dr. Hutson and Dr. Nicholas will serve as Investigators on a clinical pharmacology study to…

Psygen Announces That Psilocybin from Its Patent-Pending Process Has Been Used in Human Trial

Oct 7 • 3 min read

Quick Take: A recent clinical trial used Psygen’s patent-pending synthetic formula. The Company believes that Psygen’s patent-pending technology will improve yields and margins on revenue, and that the technology is key to scale-up and automation. Psygen Industries Ltd. provided an update today on its intellectual property portfolio and on use of psilocybin in humans. Psygen…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441